AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$27.34|
|52 Week High||US$13.96|
|52 Week Low||US$35.85|
|1 Month Change||10.33%|
|3 Month Change||3.40%|
|1 Year Change||87.26%|
|3 Year Change||-72.60%|
|5 Year Change||n/a|
|Change since IPO||60.82%|
Recent News & Updates
|ANAB||US Biotechs||US Market|
Return vs Industry: ANAB exceeded the US Biotechs industry which returned 26.1% over the past year.
Return vs Market: ANAB exceeded the US Market which returned 35.3% over the past year.
Stable Share Price: ANAB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ANAB's weekly volatility (6%) has been stable over the past year.
About the Company
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company’s products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
AnaptysBio Fundamentals Summary
|ANAB fundamental statistics|
Is ANAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANAB income statement (TTM)|
|Cost of Revenue||US$90.61m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.32|
|Net Profit Margin||-8.60%|
How did ANAB perform over the long term?See historical performance and comparison
Is AnaptysBio undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ANAB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ANAB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ANAB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ANAB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANAB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ANAB is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (3.3x).
How is AnaptysBio forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANAB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ANAB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ANAB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ANAB's revenue (12.3% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: ANAB's revenue (12.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ANAB is forecast to be unprofitable in 3 years.
How has AnaptysBio performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANAB is currently unprofitable.
Growing Profit Margin: ANAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ANAB is unprofitable, and losses have increased over the past 5 years at a rate of 23.5% per year.
Accelerating Growth: Unable to compare ANAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: ANAB has a negative Return on Equity (-2.26%), as it is currently unprofitable.
How is AnaptysBio's financial position?
Financial Position Analysis
Short Term Liabilities: ANAB's short term assets ($398.1M) exceed its short term liabilities ($20.6M).
Long Term Liabilities: ANAB's short term assets ($398.1M) exceed its long term liabilities ($20.2M).
Debt to Equity History and Analysis
Debt Level: ANAB is debt free.
Reducing Debt: ANAB has no debt compared to 5 years ago when its debt to equity ratio was 10.9%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ANAB has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ANAB is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 25.8% per year.
What is AnaptysBio current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ANAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ANAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ANAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ANAB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ANAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hamza Suria (45 yo)
Mr. Hamza Suria, M.Sc., M.B.A. has been the Chief Executive Officer and President of AnaptysBio, Inc., since July 2011. Mr. Suria served as an Acting Chief Executive Officer and Chief Business Officer of A...
CEO Compensation Analysis
Compensation vs Market: Hamza's total compensation ($USD885.39K) is below average for companies of similar size in the US market ($USD2.30M).
Compensation vs Earnings: Hamza's compensation has been consistent with company performance over the past year.
Experienced Management: ANAB's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: ANAB's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AnaptysBio, Inc.'s employee growth, exchange listings and data sources
- Name: AnaptysBio, Inc.
- Ticker: ANAB
- Exchange: NasdaqGS
- Founded: 2005
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$750.028m
- Shares outstanding: 27.43m
- Website: https://www.anaptysbio.com
Number of Employees
- AnaptysBio, Inc.
- 10421 Pacific Center Court
- Suite 200
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 22:02|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.